Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China-Developed Artificial Skin Ready For Production

This article was originally published in PharmAsia News

Executive Summary

Shaanxi Province has broken ground for its Research and Development Center for Tissue Engineering in Xi'an High-Tech Industrial Development Zone. With a total investment of RMB 120 million, the project is expected to realize a yearly revenue of RMB 1 billion when it goes into operation. The facility will have an annual output of 3 million cm2 of artificial skin, 30,000 corneas and 10 million cm2 of selective acellular double-layer dermal matrix produced by tissue engineering. Developed by Fourth Military Medical University, it is the nation's only such technology with independent intellectual property rights that can successfully produce engineered tissue products. The project makes China the second country to commercialize tissue engineering technology after the U.S. (Click here for more - Chinese Language)

You may also be interested in...

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts